The genetics of Parkinson's disease: Progress and therapeutic implications
Identifieur interne : 000F19 ( Main/Curation ); précédent : 000F18; suivant : 000F20The genetics of Parkinson's disease: Progress and therapeutic implications
Auteurs : Andrew B. Singleton [États-Unis] ; Matthew J. Farrer [Canada] ; Vincenzo Bonifati [Pays-Bas]Source :
- Movement Disorders [ 0885-3185 ] ; 2013-01.
Abstract
The past 15 years has witnessed tremendous progress in our understanding of the genetic basis for Parkinson's disease (PD). Notably, whereas most mutations, such as those in SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7, and ATP13A2, are a rare cause of disease, one particular mutation in LRRK2 has been found to be common in certain populations. There has been considerable progress in finding risk loci. To date, approximately 16 such loci exist; notably, some of these overlap with the genes known to contain disease‐causing mutations. The identification of risk alleles has relied mostly on the application of revolutionary technologies; likewise, second‐generation sequencing methods have facilitated the identification of new mutations in PD. These methods will continue to provide novel insights into PD. The utility of genetics in therapeutics relies primarily on leveraging findings to understand the pathogenesis of PD. Much of the investigation into the biology underlying PD has used these findings to define a pathway, or pathways, to pathogenesis by trying to fit disparate genetic defects onto the same network. This work has had some success, particularly in the context of monogenic disease, and is beginning to provide clues about potential therapeutic targets. Approaches toward therapies are also being provided more directly by genetics, notably by the reduction and clearance of alpha‐synuclein and inhibition of Lrrk2 kinase activity. We believe this has been an exciting, productive time for PD genetics and, furthermore, that genetics will continue to drive the etiologic understanding and etiology‐based therapeutic approaches in this disease. © 2013 Movement Disorder Society
Url:
- https://api-v5.istex.fr/document/1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578399
DOI: 10.1002/mds.25249
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000602
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000602
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000037
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000833
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000833
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000566
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001382
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001382
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001382
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :000F31
Links to Exploration step
ISTEX:1897BB23048D40AB2FDCC914B29DCA3B9F6AD5ACLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The genetics of Parkinson's disease: Progress and therapeutic implications</title>
<author><name sortKey="Singleton, Andrew B" sort="Singleton, Andrew B" uniqKey="Singleton A" first="Andrew B." last="Singleton">Andrew B. Singleton</name>
</author>
<author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name>
</author>
<author><name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/mds.25249</idno>
<idno type="url">https://api-v5.istex.fr/document/1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000602</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000602</idno>
<idno type="wicri:Area/Istex/Curation">000602</idno>
<idno type="wicri:Area/Istex/Checkpoint">000037</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000037</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Singleton A:the:genetics:of</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578399</idno>
<idno type="RBID">PMC:3578399</idno>
<idno type="wicri:Area/Pmc/Corpus">000833</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000833</idno>
<idno type="wicri:Area/Pmc/Curation">000833</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000833</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000566</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000566</idno>
<idno type="wicri:Area/Ncbi/Merge">001382</idno>
<idno type="wicri:Area/Ncbi/Curation">001382</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001382</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Singleton A:the:genetics:of</idno>
<idno type="wicri:Area/Main/Merge">000F31</idno>
<idno type="wicri:Area/Main/Curation">000F19</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The genetics of Parkinson's disease: Progress and therapeutic implications</title>
<author><name sortKey="Singleton, Andrew B" sort="Singleton, Andrew B" uniqKey="Singleton A" first="Andrew B." last="Singleton">Andrew B. Singleton</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Maryland, Bethesda</wicri:regionArea>
<wicri:noRegion>Bethesda</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Genetics, University of British Columbia, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Genetics, Rotterdam, Erasmus MC</wicri:regionArea>
<wicri:noRegion>Erasmus MC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov Disord</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-01">2013-01</date>
<biblScope unit="volume">28</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="14">14</biblScope>
<biblScope unit="page" to="23">23</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC</idno>
<idno type="DOI">10.1002/mds.25249</idno>
<idno type="ArticleID">MDS25249</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">The past 15 years has witnessed tremendous progress in our understanding of the genetic basis for Parkinson's disease (PD). Notably, whereas most mutations, such as those in SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7, and ATP13A2, are a rare cause of disease, one particular mutation in LRRK2 has been found to be common in certain populations. There has been considerable progress in finding risk loci. To date, approximately 16 such loci exist; notably, some of these overlap with the genes known to contain disease‐causing mutations. The identification of risk alleles has relied mostly on the application of revolutionary technologies; likewise, second‐generation sequencing methods have facilitated the identification of new mutations in PD. These methods will continue to provide novel insights into PD. The utility of genetics in therapeutics relies primarily on leveraging findings to understand the pathogenesis of PD. Much of the investigation into the biology underlying PD has used these findings to define a pathway, or pathways, to pathogenesis by trying to fit disparate genetic defects onto the same network. This work has had some success, particularly in the context of monogenic disease, and is beginning to provide clues about potential therapeutic targets. Approaches toward therapies are also being provided more directly by genetics, notably by the reduction and clearance of alpha‐synuclein and inhibition of Lrrk2 kinase activity. We believe this has been an exciting, productive time for PD genetics and, furthermore, that genetics will continue to drive the etiologic understanding and etiology‐based therapeutic approaches in this disease. © 2013 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000F19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC |texte= The genetics of Parkinson's disease: Progress and therapeutic implications }}
This area was generated with Dilib version V0.6.29. |